Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that it has made a $20 million strategic investment in Quantum Scan Holdings, Inc. ("Quantum Scan"), a breakthrough medical technology company, targeting trillion-dollar market of preventive diagnosis and prognosis of human diseases and illness.

The investment is intended to support Quantum Scan's ongoing efforts to identify, develop, and deploy innovative medical technologies, including advanced diagnostic platforms, integrated analytics, and scalable healthcare solutions designed to improve accessibility and efficiency across clinical and non-traditional care settings. Scilex believes this strategic investment is synergistic with its large investment in Datavault AI (NASDAQ:DVLT) ("Datavault").

• No comments yet. Be the first to comment!